Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

J. N. Ingle, L. K. Everson, S. Wieand, S. A. Cullinan, L. E. Wold, J. B. Hagen, J. K. Martin, J. E. Krook, Robert Joseph Fitzgibbons, J. F. Foley, D. L. Ahmann, D. M. Pfeifle, S. J. Green

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer. The chemotherapy regimen utilized consisted of cyclophosphamide (C), 5-fluorouracil (F), and prednisone (P), and the doses employed were: C, 150 mg/m2 IV days 1 to 5; F, 300 mg/m2 IV days 1 to 5; and P, 10 mg orally three times daily on days 1 to 7. A total of ten courses of therapy, given every 6 weeks, was planned. Tamoxifen (T) was given at a dose of 10 mg twice daily and was stopped 6 weeks after the last course of CFP. Four hundred patients are fully eligible and evaluable. With a median observation time of 5.3 years, the proportion of recurrences on each arm were: CFP, 95 of 202 (47%); CFPT, 77 of 198 (39%). The relapse-free survival distribution for CFPT was superior to that for CFP, at a borderline level of significance (two-sided P = 0.06). When significant prognostic factors were considered in covariate analysis, CFPT was not significantly better than CFP (P = 0.43). This marked change in level was due to imbalance in several factors not considered in stratification. Currently, 31% of CFP and 25% of CFPT patients have died, and although there is a slight separation of the survival curves in favor of CFPT, the difference is not significant (P = 0.21). Analysis within receptor subsets also showed no significant advantage for the addition of tamoxifen. This study does not establish a significant advantage for the concurrent administration of tamoxifen with the CFP regimen. It does, however, clearly demonstrate the importance of examination of clinically important prognostic factors, even those not utilized in stratification, and consideration of these factors in covariate analysis if imbalances are present.

Original languageEnglish
Pages (from-to)1257-1264
Number of pages8
JournalCancer
Volume63
Issue number7
StatePublished - 1989
Externally publishedYes

Fingerprint

Tamoxifen
Prednisone
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Recurrence
Survival
Mastectomy
Therapeutics
Adjuvant Chemotherapy
Combination Drug Therapy
Randomized Controlled Trials
Observation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Ingle, J. N., Everson, L. K., Wieand, S., Cullinan, S. A., Wold, L. E., Hagen, J. B., ... Green, S. J. (1989). Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer, 63(7), 1257-1264.

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. / Ingle, J. N.; Everson, L. K.; Wieand, S.; Cullinan, S. A.; Wold, L. E.; Hagen, J. B.; Martin, J. K.; Krook, J. E.; Fitzgibbons, Robert Joseph; Foley, J. F.; Ahmann, D. L.; Pfeifle, D. M.; Green, S. J.

In: Cancer, Vol. 63, No. 7, 1989, p. 1257-1264.

Research output: Contribution to journalArticle

Ingle, JN, Everson, LK, Wieand, S, Cullinan, SA, Wold, LE, Hagen, JB, Martin, JK, Krook, JE, Fitzgibbons, RJ, Foley, JF, Ahmann, DL, Pfeifle, DM & Green, SJ 1989, 'Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer', Cancer, vol. 63, no. 7, pp. 1257-1264.
Ingle, J. N. ; Everson, L. K. ; Wieand, S. ; Cullinan, S. A. ; Wold, L. E. ; Hagen, J. B. ; Martin, J. K. ; Krook, J. E. ; Fitzgibbons, Robert Joseph ; Foley, J. F. ; Ahmann, D. L. ; Pfeifle, D. M. ; Green, S. J. / Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. In: Cancer. 1989 ; Vol. 63, No. 7. pp. 1257-1264.
@article{6c6eaf3b71bb4048b33fcafeeba9903e,
title = "Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer",
abstract = "A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer. The chemotherapy regimen utilized consisted of cyclophosphamide (C), 5-fluorouracil (F), and prednisone (P), and the doses employed were: C, 150 mg/m2 IV days 1 to 5; F, 300 mg/m2 IV days 1 to 5; and P, 10 mg orally three times daily on days 1 to 7. A total of ten courses of therapy, given every 6 weeks, was planned. Tamoxifen (T) was given at a dose of 10 mg twice daily and was stopped 6 weeks after the last course of CFP. Four hundred patients are fully eligible and evaluable. With a median observation time of 5.3 years, the proportion of recurrences on each arm were: CFP, 95 of 202 (47{\%}); CFPT, 77 of 198 (39{\%}). The relapse-free survival distribution for CFPT was superior to that for CFP, at a borderline level of significance (two-sided P = 0.06). When significant prognostic factors were considered in covariate analysis, CFPT was not significantly better than CFP (P = 0.43). This marked change in level was due to imbalance in several factors not considered in stratification. Currently, 31{\%} of CFP and 25{\%} of CFPT patients have died, and although there is a slight separation of the survival curves in favor of CFPT, the difference is not significant (P = 0.21). Analysis within receptor subsets also showed no significant advantage for the addition of tamoxifen. This study does not establish a significant advantage for the concurrent administration of tamoxifen with the CFP regimen. It does, however, clearly demonstrate the importance of examination of clinically important prognostic factors, even those not utilized in stratification, and consideration of these factors in covariate analysis if imbalances are present.",
author = "Ingle, {J. N.} and Everson, {L. K.} and S. Wieand and Cullinan, {S. A.} and Wold, {L. E.} and Hagen, {J. B.} and Martin, {J. K.} and Krook, {J. E.} and Fitzgibbons, {Robert Joseph} and Foley, {J. F.} and Ahmann, {D. L.} and Pfeifle, {D. M.} and Green, {S. J.}",
year = "1989",
language = "English",
volume = "63",
pages = "1257--1264",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

AU - Ingle, J. N.

AU - Everson, L. K.

AU - Wieand, S.

AU - Cullinan, S. A.

AU - Wold, L. E.

AU - Hagen, J. B.

AU - Martin, J. K.

AU - Krook, J. E.

AU - Fitzgibbons, Robert Joseph

AU - Foley, J. F.

AU - Ahmann, D. L.

AU - Pfeifle, D. M.

AU - Green, S. J.

PY - 1989

Y1 - 1989

N2 - A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer. The chemotherapy regimen utilized consisted of cyclophosphamide (C), 5-fluorouracil (F), and prednisone (P), and the doses employed were: C, 150 mg/m2 IV days 1 to 5; F, 300 mg/m2 IV days 1 to 5; and P, 10 mg orally three times daily on days 1 to 7. A total of ten courses of therapy, given every 6 weeks, was planned. Tamoxifen (T) was given at a dose of 10 mg twice daily and was stopped 6 weeks after the last course of CFP. Four hundred patients are fully eligible and evaluable. With a median observation time of 5.3 years, the proportion of recurrences on each arm were: CFP, 95 of 202 (47%); CFPT, 77 of 198 (39%). The relapse-free survival distribution for CFPT was superior to that for CFP, at a borderline level of significance (two-sided P = 0.06). When significant prognostic factors were considered in covariate analysis, CFPT was not significantly better than CFP (P = 0.43). This marked change in level was due to imbalance in several factors not considered in stratification. Currently, 31% of CFP and 25% of CFPT patients have died, and although there is a slight separation of the survival curves in favor of CFPT, the difference is not significant (P = 0.21). Analysis within receptor subsets also showed no significant advantage for the addition of tamoxifen. This study does not establish a significant advantage for the concurrent administration of tamoxifen with the CFP regimen. It does, however, clearly demonstrate the importance of examination of clinically important prognostic factors, even those not utilized in stratification, and consideration of these factors in covariate analysis if imbalances are present.

AB - A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer. The chemotherapy regimen utilized consisted of cyclophosphamide (C), 5-fluorouracil (F), and prednisone (P), and the doses employed were: C, 150 mg/m2 IV days 1 to 5; F, 300 mg/m2 IV days 1 to 5; and P, 10 mg orally three times daily on days 1 to 7. A total of ten courses of therapy, given every 6 weeks, was planned. Tamoxifen (T) was given at a dose of 10 mg twice daily and was stopped 6 weeks after the last course of CFP. Four hundred patients are fully eligible and evaluable. With a median observation time of 5.3 years, the proportion of recurrences on each arm were: CFP, 95 of 202 (47%); CFPT, 77 of 198 (39%). The relapse-free survival distribution for CFPT was superior to that for CFP, at a borderline level of significance (two-sided P = 0.06). When significant prognostic factors were considered in covariate analysis, CFPT was not significantly better than CFP (P = 0.43). This marked change in level was due to imbalance in several factors not considered in stratification. Currently, 31% of CFP and 25% of CFPT patients have died, and although there is a slight separation of the survival curves in favor of CFPT, the difference is not significant (P = 0.21). Analysis within receptor subsets also showed no significant advantage for the addition of tamoxifen. This study does not establish a significant advantage for the concurrent administration of tamoxifen with the CFP regimen. It does, however, clearly demonstrate the importance of examination of clinically important prognostic factors, even those not utilized in stratification, and consideration of these factors in covariate analysis if imbalances are present.

UR - http://www.scopus.com/inward/record.url?scp=0024505630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024505630&partnerID=8YFLogxK

M3 - Article

C2 - 2646004

AN - SCOPUS:0024505630

VL - 63

SP - 1257

EP - 1264

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -